IL180589A0 - Use of il-28 and il-29 to treat cancer and autoimmune disorders - Google Patents

Use of il-28 and il-29 to treat cancer and autoimmune disorders

Info

Publication number
IL180589A0
IL180589A0 IL180589A IL18058907A IL180589A0 IL 180589 A0 IL180589 A0 IL 180589A0 IL 180589 A IL180589 A IL 180589A IL 18058907 A IL18058907 A IL 18058907A IL 180589 A0 IL180589 A0 IL 180589A0
Authority
IL
Israel
Prior art keywords
autoimmune disorders
treat cancer
cancer
treat
autoimmune
Prior art date
Application number
IL180589A
Other languages
English (en)
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Publication of IL180589A0 publication Critical patent/IL180589A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL180589A 2004-07-29 2007-01-08 Use of il-28 and il-29 to treat cancer and autoimmune disorders IL180589A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US59206904P 2004-07-29 2004-07-29
US62970204P 2004-11-19 2004-11-19
US67604705P 2005-04-29 2005-04-29
PCT/US2005/026951 WO2006012644A2 (en) 2004-07-29 2005-07-29 Use of il-28 and il-29 to treat cancer

Publications (1)

Publication Number Publication Date
IL180589A0 true IL180589A0 (en) 2007-06-03

Family

ID=35786785

Family Applications (1)

Application Number Title Priority Date Filing Date
IL180589A IL180589A0 (en) 2004-07-29 2007-01-08 Use of il-28 and il-29 to treat cancer and autoimmune disorders

Country Status (9)

Country Link
US (3) US7351689B2 (https=)
EP (2) EP2389944A1 (https=)
JP (1) JP2008508310A (https=)
CN (1) CN101829318B (https=)
AU (1) AU2005266892B2 (https=)
BR (1) BRPI0513865A (https=)
CA (1) CA2574564C (https=)
IL (1) IL180589A0 (https=)
WO (1) WO2006012644A2 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7038032B2 (en) 2001-04-20 2006-05-02 Zymogenetics, Inc. Cytokine protein family
US7910313B2 (en) 2001-04-20 2011-03-22 Zymogenetics, Inc. Cytokine protein family
EP2251352A1 (en) * 2003-08-07 2010-11-17 ZymoGenetics, L.L.C. Homogeneous preparations of IL-28 and IL-29
JP2008508310A (ja) * 2004-07-29 2008-03-21 ザイモジェネティクス， インコーポレイテッド がんおよび自己免疫障害を治療するためのｉｌ−２８およびｉｌ−２９の使用法
AU2006272937A1 (en) * 2005-07-20 2007-02-01 Bristol-Myers Squibb Company Use of truncated cysteine IL28 and IL29 mutants to treat cancers and autoimmune disorders
EP1912668A2 (en) * 2005-07-20 2008-04-23 ZymoGenetics, Inc. Il28 and il29 truncated cysteine mutants and antiviral methods of using same
CA2625208A1 (en) 2005-10-04 2007-04-12 Zymogenetics, Inc. Production and purification of il-29
US20080057503A1 (en) * 2006-04-24 2008-03-06 Genentech, Inc. Methods and compositions for detecting autoimmune disorders
AU2008301229B2 (en) * 2007-09-20 2013-10-10 Australian Poultry Crc Pty Ltd Novel avian cytokines and genetic sequences encoding same
US8354125B2 (en) 2007-10-27 2013-01-15 Grant Gallagher Ex-vivo treatment of peripheral blood leukocytes with IFN-λ
KR101652767B1 (ko) 2008-04-04 2016-08-31 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Ｉｌ-28을 이용한 백신 및 면역치료제, 및 그를 사용하는 방법 및 조성물
AU2009255994B2 (en) * 2008-06-05 2014-07-17 Bristol-Myers Squibb Company Use of pegylated Type III Interferons for the treatment of hepatitis C
US20100316604A1 (en) * 2009-04-21 2010-12-16 Asterion Limited Interferon lambda fusion polypeptides
US9544143B2 (en) 2010-03-03 2017-01-10 Duo Security, Inc. System and method of notifying mobile devices to complete transactions
US9532222B2 (en) 2010-03-03 2016-12-27 Duo Security, Inc. System and method of notifying mobile devices to complete transactions after additional agent verification
JP5821198B2 (ja) * 2011-01-27 2015-11-24 富士レビオ株式会社 抗ｉｌ２８ｂ抗体及びこれを用いたｉｌ２８ｂの測定方法
WO2013029062A1 (en) * 2011-08-25 2013-02-28 Nanogen Pharmaceutical Biotechnology Co., Ltd Peginterferon lambda 1 conjugates, processes for their preparation, pharmaceutical compositions containing these conjugates and processes for making the same
US9467463B2 (en) 2011-09-02 2016-10-11 Duo Security, Inc. System and method for assessing vulnerability of a mobile device
CA2891974A1 (en) 2012-11-21 2014-05-30 The Governors Of The University Of Alberta Immunomodulatory peptides and methods of use thereof
CN103898123B (zh) * 2012-12-28 2019-03-15 北京韩美药品有限公司 重组人IFN-β-1a及其生产和纯化方法
CN109293782A (zh) * 2014-01-08 2019-02-01 德益阳光生物技术（北京）有限责任公司 融合多肽及使用方法
ES2758755T3 (es) 2015-06-01 2020-05-06 Duo Security Inc Método para aplicar normas de salud de punto final
US11292823B2 (en) 2017-05-01 2022-04-05 Rutgers, The State University Of New Jersey Type I and type III interferon fusion molecules and methods for use thereof
US10412113B2 (en) 2017-12-08 2019-09-10 Duo Security, Inc. Systems and methods for intelligently configuring computer security
US11658962B2 (en) 2018-12-07 2023-05-23 Cisco Technology, Inc. Systems and methods of push-based verification of a transaction
WO2021119749A1 (en) * 2019-12-20 2021-06-24 The Council Of The Queensland Institute Of Medical Research Treatment of gastrointestinal disease
CN112694526B (zh) * 2020-05-27 2023-01-20 杭州先为达生物科技有限公司 一种白细胞介素29突变体蛋白
CN112870336B (zh) * 2021-02-24 2022-06-14 杭州先为达生物科技有限公司 一种白细胞介素29突变体蛋白制剂
CN115252764A (zh) * 2022-08-09 2022-11-01 南方医科大学 一种白介素在制备治疗急性髓系白血病的药物中的应用

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES8308534A1 (es) 1980-01-08 1983-09-01 Biogen Nv Un metodo de producir un polipeptido que exhibe actividad inmunologica o biologica del interferon de leucocitos humanos.
US4615974A (en) 1981-08-25 1986-10-07 Celltech Limited Yeast expression vectors
US4579821A (en) 1981-11-23 1986-04-01 University Patents, Inc. Control of DNA sequence transcription
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US4486533A (en) 1982-09-02 1984-12-04 St. Louis University Filamentous fungi functional replicating extrachromosomal element
US4599311A (en) 1982-08-13 1986-07-08 Kawasaki Glenn H Glycolytic promotersfor regulated protein expression: protease inhibitor
US4977092A (en) 1985-06-26 1990-12-11 Amgen Expression of exogenous polypeptides and polypeptide products including hepatitis B surface antigen in yeast cells
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
WO1985003934A1 (fr) * 1984-03-06 1985-09-12 Takeda Chemical Industries, Ltd. Proteine modifiee chimiquement et son procede de preparation
US4661454A (en) 1983-02-28 1987-04-28 Collaborative Research, Inc. GAL1 yeast promoter linked to non galactokinase gene
US5139936A (en) 1983-02-28 1992-08-18 Collaborative Research, Inc. Use of the GAL1 yeast promoter
US4870008A (en) 1983-08-12 1989-09-26 Chiron Corporation Secretory expression in eukaryotes
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US4931373A (en) 1984-05-25 1990-06-05 Zymogenetics, Inc. Stable DNA constructs for expression of α-1 antitrypsin
US4766073A (en) 1985-02-25 1988-08-23 Zymogenetics Inc. Expression of biologically active PDGF analogs in eucaryotic cells
DE3578435D1 (de) 1984-12-06 1990-08-02 Labofina Sa Promotoren fuer die expression von fremden genen in hefe, plasmide, die diese promotoren enthalten, sowie deren verwendung zur herstellung von polypeptiden.
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US5206344A (en) * 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4882279A (en) 1985-10-25 1989-11-21 Phillips Petroleum Company Site selective genomic modification of yeast of the genus pichia
US4935349A (en) 1986-01-17 1990-06-19 Zymogenetics, Inc. Expression of higher eucaryotic genes in aspergillus
GB8611832D0 (en) 1986-05-15 1986-06-25 Holland I B Polypeptide
US5063154A (en) 1987-06-24 1991-11-05 Whitehead Institute For Biomedical Research Pheromone - inducible yeast promoter
US6018026A (en) 1988-01-22 2000-01-25 Zymogenetics, Inc. Biologically active dimerized and multimerized polypeptide fusions
US5750375A (en) 1988-01-22 1998-05-12 Zymogenetics, Inc. Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions
US5567584A (en) 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
US4956288A (en) 1988-04-22 1990-09-11 Biogen, Inc. Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA
US5037743A (en) 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
US5162228A (en) 1988-12-28 1992-11-10 Takeda Chemical Industries, Ltd. Gylceraldehyde-3-phosphate dehydrogenase gene and promoter
US5162222A (en) 1989-07-07 1992-11-10 Guarino Linda A Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells or recombinant baculoviruses
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
US5298418A (en) 1991-09-16 1994-03-29 Boyce Thompson Institute For Plant Research, Inc. Cell line isolated from larval midgut tissue of Trichoplusia ni
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
WO1994006463A1 (en) 1992-09-14 1994-03-31 Pfizer Inc Immortalized cells and uses therefor
US5738846A (en) 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
US5641655A (en) 1994-11-30 1997-06-24 Zymogenetics, Inc. Methods for producing thrombopoietin polypeptides using a mammalian tissue plasminogen activator secretory peptide
US5965389A (en) 1995-11-09 1999-10-12 Zymogenetics, Inc. Production of GAD65 in methylotrophic yeast
US6001597A (en) 1995-11-09 1999-12-14 Zymogenetics, Inc. Compositions and methods for producing heterologous polypeptides in Pichia methanolica
US5955349A (en) 1996-08-26 1999-09-21 Zymogenetics, Inc. Compositions and methods for producing heterologous polypeptides in Pichia methanolica
US5736383A (en) 1996-08-26 1998-04-07 Zymogenetics, Inc. Preparation of Pichia methanolica auxotrophic mutants
CN1230997A (zh) 1996-07-17 1999-10-06 津莫吉尼蒂克斯公司 甲醇毕赤酵母的转化
US5945511A (en) 1997-02-20 1999-08-31 Zymogenetics, Inc. Class II cytokine receptor
US5965704A (en) 1997-08-05 1999-10-12 Zymogenetics, Inc. Class two cytokine receptor-11
US6307024B1 (en) 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
DE60135393D1 (de) 2000-06-30 2008-09-25 Zymogenetics Inc Allelische Variante des Interferon-ähnlichen Proteins Zcyto21
ATE549347T1 (de) 2000-09-08 2012-03-15 Schering Corp Gene von säugetiere, und damit verbundene reagentien, methoden
JP2004532611A (ja) 2000-11-28 2004-10-28 ザイモジェネティクス，インコーポレイティド サイトカイン受容体ｚｃｙｔｏｒ１９
US7038032B2 (en) * 2001-04-20 2006-05-02 Zymogenetics, Inc. Cytokine protein family
EP1942187B1 (en) * 2001-04-20 2010-09-22 ZymoGenetics, L.L.C. Cytokine protein family
WO2002092762A2 (en) 2001-05-10 2002-11-21 Immunex Corporation Cytokine polypeptides
CA2462687A1 (en) 2001-10-02 2003-04-17 Mochida Pharmaceutical Co., Ltd. Novel class ii cytokine receptor
TW200300170A (en) 2001-11-09 2003-05-16 Wyeth Corp Type 2 cytokine receptor and nucleic acids encoding same
WO2003066002A2 (en) 2002-02-08 2003-08-14 University Of Medicine And Dentistry Of New Jersey IFN-a/b-INDEPENDENT MECHANISM OF ANTIVIRAL PROTECTION
CN1659274A (zh) 2002-04-19 2005-08-24 津莫吉尼蒂克斯公司 细胞因子受体
CA2503305A1 (en) * 2002-10-23 2004-05-06 Zymogenetics, Inc. Methods for treating viral infection using il-28 and il-29
US20040224914A1 (en) 2003-04-18 2004-11-11 The University Of British Columbia Method for treatment of angiogenic disorders
EP2251352A1 (en) * 2003-08-07 2010-11-17 ZymoGenetics, L.L.C. Homogeneous preparations of IL-28 and IL-29
JP2008508310A (ja) 2004-07-29 2008-03-21 ザイモジェネティクス， インコーポレイテッド がんおよび自己免疫障害を治療するためのｉｌ−２８およびｉｌ−２９の使用法

Also Published As

Publication number Publication date
BRPI0513865A (pt) 2008-05-20
US7786075B2 (en) 2010-08-31
JP2008508310A (ja) 2008-03-21
EP2389944A1 (en) 2011-11-30
CA2574564A1 (en) 2006-02-02
WO2006012644A2 (en) 2006-02-02
US8361954B2 (en) 2013-01-29
US20100291030A1 (en) 2010-11-18
AU2005266892B2 (en) 2011-03-03
AU2005266892A1 (en) 2006-02-02
US7351689B2 (en) 2008-04-01
US20080167244A1 (en) 2008-07-10
EP1793845A2 (en) 2007-06-13
US20060024269A1 (en) 2006-02-02
CA2574564C (en) 2013-04-16
CN101829318B (zh) 2012-07-04
WO2006012644A3 (en) 2007-02-01
CN101829318A (zh) 2010-09-15

Similar Documents

Publication Publication Date Title
IL180589A0 (en) Use of il-28 and il-29 to treat cancer and autoimmune disorders
IL188357A0 (en) Use of truncated cysteine il28 and il29 mutants to treat cancers and autoimmune disorders
IL178012A0 (en) Diphenyl-indol-2-on compounds and their use in the treatment of cancer
IL190733A0 (en) Methods and compositions for use in treatment of patients with autoantibody positive diseases
EP1816996A4 (en) THERAPEUTIC METHODS AND COMPOSITIONS COMPRISING PLANT EXTRACTS FOR THE TREATMENT OF CANCER
PT2601961T (pt) Composições compreendendo lag-3 e anticorpos terapêuticos e as suas utilizações no tratamento de cancro
IL210090A0 (en) TREATMENT OF TNFa RELATED DISORDERS
ZA200705123B (en) Rapamycin derivatives and the uses thereof in the treatment of neurological disorders
IL178758A0 (en) Use of flibanserin in the treatment of premenstrual and other female sexual disorders
EP1827362A4 (en) COMPOSITIONS AND METHODS OF USE FOR IMPROVING THE STATE AND THE APPEARANCE OF THE SKIN
IL182222A0 (en) Treatment of bipolar disorders and associated symptoms
IL177849A0 (en) Methods and compositions for treatment of autoimmune diseases
IL165394A0 (en) Use of thio-oxindole derivatives in treatment of skin disorders
EP1594897A4 (en) USE OF IL-6 ANTAGONISTS IN COMBINATION WITH STEROIDS FOR INCREASED APOPTOSIS
AP2715A (en) Use of imatinib to treat liver disorders and viralinfections
EP1789047A4 (en) PROCESS FOR TREATING DISEASES USING NALMEFENE AND ITS ANALOGUES
EP1733045A4 (en) DESIGN AND THERAPEUTIC USE OF ADPASE-ENHANCED APYRASES
IL193943A0 (en) The use of beta- aminoalcohols for the treatment of inflammatory disorders and pain
AU2003286600A8 (en) Prkcb1 as modifier of branching morphogenesis and methods of use
EP1539100A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF SKIN DISORDERS
GB0419828D0 (en) The treatment of inflammatroy disorders and pain
EP1583543A4 (en) METHOD AND THERAPEUTIC COMPOSITIONS IN THE TREATMENT OF ADVANCED CARCINOMA
IL193944A0 (en) The use beta-aminoalcohols for the treatment of inflammatory disorders and pain
EP1718329A4 (en) METHOD FOR THE TREATMENT OF SKIN DISEASES
IL164099A0 (en) Use of interleukin-19 to treat cervical cancer